Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.70 |
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.70 |
| ▸ | RELA | Q04206 | 4/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | BRD4 | O60885 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.63 |
| ▸ | MPI | P34949 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366875 | 1.00 | MAOB (0.81) | MAOBKDM4EMAPTL3MBTL1NFKB1 | |
| SCHEMBL2518179 | 0.89 | KDM4E (0.86) | MAOBKDM4EMAPTL3MBTL1NFKB1 | |
| Hydrochloric Acid SCHEMBL5594620 | 0.88 | KDM4E (0.83) | MAOBKDM4EMAPTL3MBTL1NFKB1 | |
| SCHEMBL5594566 | 0.85 | KDM4E (0.89) | MAOBKDM4EMAPTL3MBTL1NFKB1 | |
| SCHEMBL24716091 | 0.84 | KDM4E (0.97) | KDM4EMAPTL3MBTL1NFKB1NFKB2 | |
| SCHEMBL30626619 | 0.84 | KDM4E (0.97) | KDM4EMAPTL3MBTL1NFKB1NFKB2 | |
| SCHEMBL5595451 | 0.83 | KDM4E (0.75) | KDM4EMAPTL3MBTL1NFKB1NFKB2 | |
| SCHEMBL13310328 | 0.83 | KDM4E (0.75) | KDM4EMAPTL3MBTL1NFKB1NFKB2 | |
| SCHEMBL5595007 | 0.83 | KDM4E (0.78) | KDM4EMAPTL3MBTL1NFKB1NFKB2 | |
| SCHEMBL113982 | 0.83 | MAPT (0.60) | MAOBKDM4EMAPTL3MBTL1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383415-B1 | USE OF MITOCHONDRIAL IRON CHELATORS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | UNIV CORNELL (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10905682-B2 | Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease | CORNELL UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| US-20180360815-A1 | USE OF MITOCHONDRIAL IRON CHELATORS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-12-20 | — | — | US | disclosed |
| US-10155936-B2 | Parkin ligase activation methods and compositions | An2H Discovery Limited (IE) | 2018-12-18 | — | — | US | disclosed |
| EP-3383415-A1 | USE OF MITOCHONDRIAL IRON CHELATORS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Cornell University (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017096013-A1 | USE OF MITOCHONDRIAL IRON CHELATORS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | CORNELL UNIVERSITY (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| WO-2010086860-A2 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-08-05 | — | — | WO | disclosed |
| US-20060234927-A1 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-10-19 | — | — | US | disclosed |
| US-20050191348-A1 | Use of propargylamine as neuroprotective agent | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-09-01 | — | — | US | disclosed |
| EP-1565185-A2 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004041151-A2 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155936-B2 | Parkin ligase activation methods and compositions | PINK1, XIAP, STUB1 | MAOB 1584/4885KDM4E 2210/4885MAPT 1156/4885 |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | GSR, GRIN1, GRIN2A | MAOB 12/4885KDM4E 3218/4885MAPT 1195/4885 |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MAOB 1584/4885KDM4E 2210/4885MAPT 1156/4885 |
| US-20060234927-A1 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | FECH, HMOX1, FTH1 | MAOB 1223/4885KDM4E 3557/4885MAPT 684/4885 |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MAOB 1584/4885KDM4E 2210/4885MAPT 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.